Physician profile
Frederick Harold
NPI 1629484902
$3,807.68
in general payments reported to CMS, 2019-2025
29 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $135 · 2021: $375 · 2022: $1,311 · 2023: $717 · 2024: $720 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $641.95 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $492.84 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $280.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $238.30 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $221.19 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $219.03 | 2022-2023 | |
| Lilly USA, LLC | $216.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $200.93 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.04 | 2021-2025 | Jardiance |
| Cequr Corporation | $121.62 | 2023 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $118.72 | 2020-2024 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $111.61 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.30 | 2022-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $98.66 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $91.84 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.47 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $54.97 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $48.10 | 2022 | |
| Corcept Therapeutics | $47.39 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $46.27 | 2021 | |
| Astellas Pharma US INC | $44.29 | 2025 | Veozah |
| Daiichi Sankyo INC. | $40.56 | 2021-2022 | |
| Amarin Pharma, INC. | $36.87 | 2021-2022 | |
| Eisai INC. | $36.48 | 2021 | |
| Abbott Laboratories | $21.88 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $21.43 | 2024 | Eliquis |
| Xeris Pharmaceuticals, INC. | $17.48 | 2021 | |
| Medtronic, INC. | $17.40 | 2024 | Interstim |
| Janssen Pharmaceuticals, INC | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Harold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.